1. Home
  2. ADSE vs LBRX Comparison

ADSE vs LBRX Comparison

Compare ADSE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADS-TEC ENERGY PLC

ADSE

ADS-TEC ENERGY PLC

HOLD

Current Price

$12.46

Market Cap

847.5M

ML Signal

HOLD

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$33.39

Market Cap

958.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADSE
LBRX
Founded
1980
2015
Country
Ireland
United States
Employees
302
27
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
847.5M
958.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADSE
LBRX
Price
$12.46
$33.39
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$46.60
AVG Volume (30 Days)
9.3K
323.7K
Earning Date
05-01-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$549.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.89
$13.40
52 Week High
$13.50
$34.00

Technical Indicators

Market Signals
Indicator
ADSE
LBRX
Relative Strength Index (RSI) 62.77 68.82
Support Level $11.20 $26.75
Resistance Level $13.50 $33.47
Average True Range (ATR) 0.69 1.79
MACD 0.14 0.40
Stochastic Oscillator 88.93 91.40

Price Performance

Historical Comparison
ADSE
LBRX

About ADSE ADS-TEC ENERGY PLC

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: